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ABSTRACT
Background Current data concerning maternal
paracetamol intake during pregnancy, or intake during
infancy and risk of wheezing or asthma in childhood is
inconclusive based on epidemiological studies. We have
investigated whether there is a causal link between
maternal paracetamol intake during pregnancy and
lactation and the development of house dust mite (HDM)
induced allergic airways disease (AAD) in offspring using
a neonatal mouse model.
Methods Pregnant mice were administered
paracetamol or saline by oral gavage from the day of
mating throughout pregnancy and/or lactation.
Subsequently, their pups were exposed to intranasal
HDM or saline from day 3 of life for up to 6 weeks.
Assessments of airway hyper-responsiveness,
inﬂammation and remodelling were made at weaning
(3 weeks) and 6 weeks of age.
Results Maternal paracetamol exposure either during
pregnancy and/or lactation did not affect development of
AAD in offspring at weaning or at 6 weeks. There were
no effects of maternal paracetamol at any time point on
airway remodelling or IgE levels.
Conclusions Maternal paracetamol did not enhance
HDM induced AAD in offspring. Our mechanistic data do
not support the hypothesis that prenatal paracetamol
exposure increases the risk of childhood asthma.
INTRODUCTION
An association between paracetamol use in preg-
nancy and increased risk of early childhood wheez-
ing was ﬁrst reported in a large population-based
birth cohort study several years ago.1 Paracetamol
exposure in late gestation was subsequently asso-
ciated with an increased risk of doctor-diagnosed
asthma and elevated total IgE at 7 years, but not
allergen skin test positivity, lung function or bron-
chial responsiveness; early gestational exposure was
associated with an increased risk of asthma but not
raised IgE.2 3 It has been argued that confounding
by unmeasured behavioural factors linked to para-
cetamol use is an unlikely explanation for these
ﬁndings.4 Some evidence has recently been
reported for interactions between maternal antioxi-
dant gene polymorphisms and prenatal paracetamol
exposure on childhood asthma risk, thus strength-
ening the likelihood of causality.3 5 Since the ori-
ginal report, a body of epidemiological evidence
from other birth cohort studies has accumulated,6
with most,5 7 8 though not all,9 conﬁrming a link
between prenatal exposure and subsequent asthma
or wheezing.
Infant paracetamol exposure has also been linked
longitudinally to later wheezing and asthma,10–12
independently of the effect of prenatal exposure3
and also to atopy.3 13 While the most likely explan-
ation for the association with asthma is confound-
ing by early respiratory infection,12–14 we cannot
rule out the possibility that paracetamol exposure,
perhaps in synergy with viral infection, might
promote persistence of wheezing.
While deﬁnitive evidence of a causal link can
only come from trials in humans, primary preven-
tion trials in pregnancy and infancy pose consider-
able challenges; one immediate way forward is to
carry out experimental studies in animal models.6
In an adult mouse model it was demonstrated that
paracetamol, in the equivalent of human thera-
peutic doses could, via its reactive metabolite, acti-
vate the transient receptor potential ankyrin-1
channel, leading to neurogenic airway inﬂamma-
tion, thus offering an alternative potential mechan-
ism by which paracetamol might inﬂuence asthma
pathogenesis.15 Using an established and charac-
terised neonatal model of house dust mite (HDM)
induced allergic airways disease (AAD)16 we have
investigated whether maternal exposure to para-
cetamol during pregnancy and lactation promotes
the development of AAD in the offspring.
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Key messages
What is the key question?
▸ Does paracetamol exposure during pregnancy
or lactation lead to the development of allergic
airways disease in early life?
What is the bottom line?
▸ Maternal exposure to paracetamol, either
during pregnancy, or lactation, or both, does
not affect development of house dust mite
induced allergic airways disease in neonatal
mice.
Why read on?
▸ This is the ﬁrst mechanistic study to investigate
a causal link between prenatal and early life
paracetamol exposure and the subsequent
development of allergic airways disease.
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MATERIALS AND METHODS
Animals and paracetamol administration
BALB/c mice were housed at Imperial College animal facility and
used at 8–16 weeks of age. Female mice were administered
100 mL of liquid paracetamol (Calpol) (120 mg/5mLs paraceta-
mol) or phosphate-buffered saline (PBS) by oral gavage either
during pregnancy or lactation alone (ﬁgure 1), or both during
pregnancy and lactation (ﬁgure 2). The dose of paracetamol was
based upon the maximum recommended dose of 60 mg/kg/day
for an average human. The potential effects of oral gavage in indu-
cing stress during pregnancy were assessed by including a group of
naïve pregnant females that underwent no treatment. Since there
was no signiﬁcant effect of oral gavage alone, data for PBS treated
and naïve mothers were combined. In order to mimic ﬁndings
from the epidemiological data which only showed effects with fre-
quent and regular maternal paracetamol use, we administered
Figure 1 Similar airway hyper-responsiveness (AHR) following paracetamol exposure during either pregnancy or lactation. Experimental protocol
for paracetamol exposure during pregnancy (A). Pregnant females were treated with 100 mL of 1.2 mg/mL liquid paracetamol by oral gavage 5 days
a week, with a break on day 4 and day 7, during pregnancy (↑). Neonates were challenged with either house dust mite (HDM) or phosphate-
buffered saline (PBS) intranasally on day 3 of life, three times a week for 3 weeks (↓). AHR measured as (B and E) lung resistance and (C and F)
dynamic compliance to increasing doses of methacholine was determined 4 h after the last HDM challenge. Experimental protocol for paracetamol
exposure during lactation (D). Female mice were mated and left for the duration of the pregnancy. On the day of birth, mothers were treated with
100 mL of 1.2 mg/mL liquid paracetamol by oral gavage 5 days a week, with a break on day 4 and day 7, during lactation, neonates were
challenged with PBS or HDM from day 3 of life. Combined data of at least two experiments (n=10 for control mice and n=16–24 for HDM-exposed
mice). No signiﬁcant differences were found.
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paracetamol on 5 days every week. Litters were housed with their
mothers until weaned at 3 weeks. All mice and litters were main-
tained in speciﬁc pathogen-free conditions and given food and
water ad libitum. UK Home Ofﬁce guidelines for animal welfare
based on the Animals Scientiﬁc Procedures act 1986 were
observed.
Induction of AAD
Pups were exposed to 10 mg (10 mL of 1 mg/mL protein weight
solution in PBS) of puriﬁed HDM extract (Greer Laboratories,
Lenoir, North Carolina, USA) or PBS intranasally from day 3 of
life for 3 days/week for 2 weeks, followed by 15 μg for up to 3
weeks or 6 weeks.16
Measurement of AHR
Airway hyper-responsiveness (AHR) was measured as a terminal
procedure 4 h after last allergen challenge in response to
increasing doses of methacholine (3–100 mg/mL, Sigma, Poole,
UK) in tracheostomised, anaesthetised mice using a Flexivent
system (Scireq, Montreal, Canada) as described previously.16
Cell recovery
Airway Lumen
Bronchoalveolar lavage (BAL) was performed using three ali-
quots of 0.3 mL PBS for 3-week-old mice and 0.4 mL PBS for
6-week-old mice, via a tracheal cannula. BAL ﬂuid was centri-
fuged (200×g, 5 min at 4°C), supernatants were stored at −80°
C for cytokine analysis and cells were resuspended in 0.5 mL
complete media (Roswell Park Memorial Institute medium
(RPMI)+10% fetal calf serum (FCS), 2 mM L-Glutamine,
100 U/mL Penicillin/Streptomycin).
Lung parenchyma
One lobe of lung tissue was mechanically chopped and incu-
bated at 37°C for 1 h in complete media containing 0.15 mg/mL
collagenase (Type D, Roche Diagnostics, Lewes, UK) and 25 μg/
mL DNase (Type 1, Roche Diagnostics). Cells were recovered by
ﬁltration through a 70 μm nylon sieve, washed twice and resus-
pended in 1 mL complete media.
Serum
Blood was collected by cardiac puncture and transferred into a
microtainer with serum separation gel (BD, Fischer scientiﬁc).
Tubes were centrifuged at 14 000 RPM for 5 min to separate
serum. Tubes were then stored at −20°C prior to analysis of
immunoglobulins.
Cytocentrifuge preparation and differential counts of
Wright-Giemsa stained BAL and lung cells
Lung and BAL cells were applied to glass slides by centrifuga-
tion and stained with Wright-Giemsa (Thermo Fisher Scientiﬁc,
Waltham, Massachusetts, USA). Percentages of macrophages,
lymphocytes/mononuclear cells, eosinophils and neutrophils
were determined under 40× magniﬁcation by counting cells in
randomly selected ﬁelds and dividing this number by the total
number of cells (400) counted. To obtain absolute numbers, this
percentage was multiplied by the total number of cells recovered
in lavage ﬂuid and lung digest suspension. All cell counts were
performed blind by the same observer.
Analysis of cytokines
Cytokines were analysed in BAL samples and lung tissue hom-
ogenate supernatants. Lung tissue was homogenised at 50 mg/
mL in Hank’s balanced salt solution (HBSS) containing protease
inhibitor tablets (Roche Diagnostics), centrifuged (800×g,
10 min) and the supernatant collected. BAL and lung homogen-
ate cytokine levels were measured using paired antibodies for
murine interleukin (IL) 4, IL-5, IL-25, IL-33 and interferon
(IFN)-γ (BD Bioscience UK and R&D Systems, Abingdon, UK)
in standardised sandwich ELISAs according to the manufac-
turer’s protocol. Kits to measure IL-13 were purchased from
R&D Systems. Paired antibodies for IgE (R&D systems) were
used to measure serum IgE levels.
Total lung collagen levels
Recently synthesised acid-soluble collagen was measured in the
lung by biochemical assay (Sircol collagen assay; Biocolor,
Belfast, UK) according to manufacturer’s instructions and nor-
malised for tissue weight.
RNA extraction and qPCR
Total RNA was extracted from 50 mg to 100 mg of lung tissue
by using a Qiagen RNeasy Mini Kit. Total RNA (1 μg) was
reverse transcribed into cDNA using a High Capacity cDNA
Reverse Transcription Kit (Life Technologies) as per the manu-
facturer’s instructions. Real-time PCR reactions were performed
using fast-qPCR mastermix (Life technologies) on a Viaa-7 (Life
Technologies) instrument with TaqMan primer sets for murine
amphiregulin, matrix metallopeptidase 2 (MMP-2), ﬁbronectin,
Found In Inﬂammatory Zone (FIZZ)1, vimentin, collagen-1α1
and Hypoxanthine-guanine phosphoribosyltransferase (HPRT)
(Life Technologies) and gene expression was analysed using the
change-in-threshold ΔΔCt- method.
Figure 2 Experimental protocol for
paracetamol exposure during
pregnancy and lactation. Female BALB/
c mice aged 6–8 weeks were treated
with 100 mL of 1.2 mg/mL liquid
paracetamol by oral gavage 5 days a
week, with a break on day 4 and day
7, during pregnancy and lactation (↑).
Neonatal mice were treated with either
house dust mite (HDM) or phosphate-
buffered saline (PBS) intranasally from
day 3 of life, three times a week for
either 3 weeks or 6 weeks (↓).
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Figure 3 Allergic airways disease
characterisation in house dust mite
(HDM)-exposed neonatal mice from
paracetamol-treated mothers. Airway
hyper-responsiveness (AHR) in
response to increasing doses of
methacholine measured as lung
resistance (A and B) and compliance
(C and D) following 3 weeks or
6 weeks of HDM or phosphate-
buffered saline (PBS) exposure, was
determined in pups from either
paracetamol-treated or
non-paracetamol-treated mothers.
Total inﬂammatory cells in the lung
(E and F), total number of lung
eosinophils (G and H) and total
inﬂammatory cells in the
bronchoalveolar lavage (BAL, I and J)
were assessed at 3 weeks and
6 weeks. Combined data from two
experiments (○ naïve females and ▪
PBS treated females) or
paracetamol-treated mothers (◊ and
▾); (n=10–12 for control mice and
n=11–15 for HDM-exposed mice).
Horizontal bars represent median.
There were no statistically signiﬁcant
differences between neonates exposed
to paracetamol and those without
paracetamol exposure at any time
point.
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Statistical analysis
Data are expressed as median or mean±SEM. Group comparisons
were performed using a non-parametric analysis of variance
(ANOVA) test (Kruskal-Wallis), followed by a Dunn’s post test for
multiple comparisons between groups. Graph generation and statis-
tical analyses were performed using GraphPad Prism software
(V.5.00; GraphPad).
RESULTS
Maternal paracetamol exposure during pregnancy alone did
not affect AHR in neonatal mice
In order to determine whether prenatal exposure to paracetamol
during pregnancy altered lung function in neonatal mice
exposed to HDM, pregnant females were treated with paraceta-
mol on the 1st day of mating and throughout pregnancy.
Paracetamol treatment was stopped on the day they gave birth.
Offspring were exposed to intranasal PBS or HDM from day 3
of life, for 3 weeks (ﬁgure 1A). In utero paracetamol exposure
alone did not result in worse lung function in HDM-exposed
neonatal mice at weaning (3 weeks) (ﬁgure 1B, C).
Maternal paracetamol exposure during lactation alone did
not affect AHR in neonatal mice
Therefore, exposure during lactation was investigated to deter-
mine the inﬂuence of oral ingestion in the neonate via breast
milk.17 Female mice were mated and left for the duration of the
pregnancy. On the day of birth, mothers received the ﬁrst dose of
oral paracetamol which continued for 3 weeks. Pups were
exposed to either intranasal PBS or HDM (ﬁgure 1D).
HDM-exposed pups from paracetamol-treated mothers had
similar AHR compared with those from PBS-treated mothers
(ﬁgure 1E, F). There was no effect of paracetamol on inﬂamma-
tion in the BAL or lung (see online supplementary ﬁgure S1A,B),
levels of IL-13 or IL-33 in the lungs (see online supplementary
ﬁgure S1C,D), or total IgE and HDM-speciﬁc IgE (see online
supplementary ﬁgure S1E, F).
Maternal paracetamol exposure during pregnancy and
lactation does not affect AAD in offspring
As paracetamol exposure during pregnancy or lactation alone
had no effect on neonatal AAD, additive effects of perinatal
Figure 4 Levels of Th2 and innate
cytokines in the lung. The levels of
interleukin (IL) 5 (A and D), IL-13
(B and E) and IL-33 (C and F) in
neonatal lung homogenate
supernatant from
non-paracetamol-treated (○ naïve
females and ▪ phosphate-buffered
saline (PBS) treated females) or
paracetamol-treated mothers (◊ and
▾) were assessed by ELISA at 3 weeks
and 6 weeks. Combined data from two
experiments (n=10–12 for control mice
and n=11–15 for house dust mite
(HDM)-exposed mice). Signiﬁcant
differences between HDM-exposed and
PBS-exposed neonates from
non-paracetamol-treated or
paracetamol-treated mothers are
shown as **p<0.01 and ***p<0.001.
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exposure during pregnancy and lactation were determined in
early life (3 weeks) and in young adulthood (6 weeks) (ﬁgure 2).
HDM-exposed pups from mothers treated with paracetamol
during pregnancy and lactation had similar airway resistance
and compliance at 3 weeks and 6 weeks compared with those
from naïve or PBS-treated mothers (ﬁgure 3A–D). The total
number of inﬂammatory cells recruited to the lung and BAL
and eosinophils in the lung were unaffected by maternal para-
cetamol at 3 weeks and 6 weeks (ﬁgure 3E–J).
Maternal paracetamol exposure during pregnancy and
lactation does not alter neonatal inﬂammatory cytokines
or IgE
The Th2 cytokines IL-5 and IL-13 were measured in BAL and
lung and were signiﬁcantly increased in HDM-exposed neonatal
mice compared with PBS controls at 3 weeks, but maternal para-
cetamol did not alter levels of BAL (data not shown) or lung
IL-5 or IL-13 (ﬁgure 4A, B). The same was true for the innate
cytokine IL-33 (ﬁgure 4C). At 6 weeks levels of IL-5, IL-13 and
IL-33 were still increased in HDM-treated groups, compared
with controls (ﬁgure 4D–F), but there was no additional effect
of maternal paracetamol. At 3 weeks and 6 weeks serum total
IgE levels were signiﬁcantly higher in HDM-exposed neonatal
mice compared with controls, but there was no impact of mater-
nal paracetamol exposure on total IgE levels (ﬁgure 5A). The
same was also true for HDM speciﬁc IgE levels following 3 and
6 weeks of HDM exposure (ﬁgure 5B).
Maternal paracetamol did not affect airway remodelling in
HDM-exposed neonatal mice
Increased subepithelial reticular membrane thickness is an early
feature of airway remodelling in preschool wheeze18 and child-
hood asthma,19 we therefore analysed mRNA levels of genes
associated with remodelling including FIZZ1,20 ﬁbronectin,21
vimentin,22 MMP-2,23 amphiregulin24 and collagen-1α1,25 from
neonatal mice exposed to paracetamol during pregnancy alone
(ﬁgure 1A), or lactation alone (ﬁgure 1D). Paracetamol treatment
during pregnancy or lactation led to an upregulation of FIZZ1
expression in 3 week old HDM-treated neonates, in comparison
to PBS-treated controls (ﬁgure 6A). Minimal changes were
observed in the expression of vimentin and ﬁbronectin, following
3 weeks of HDM in mice exposed to paracetamol in utero, in
comparison to PBS exposed controls (ﬁgure 6B,C). However,
these alterations did not lead to lung function changes (ﬁgure 1
and see online supplementary ﬁgure S2A–D). Importantly, the
effect of paracetamol exposure was transient and was not
observed following 6 weeks of HDM exposure. Expression levels
of amphiregulin, MMP-2 and collagen-1α1 were unaffected by
paracetamol exposure following 3 weeks or 6 weeks of HDM
treatment (ﬁgure 6D–F). In order to determine whether differ-
ences in protein were present, total lung collagen was quantiﬁed
by biochemical assay. Maternal paracetamol treatment during
pregnancy, lactation, or both, had no impact on collagen levels in
neonatal mice exposed to HDM for 3 weeks (ﬁgure 7A–C) or in
young adulthood at week 6 (ﬁgure 7D).
DISCUSSION
To our knowledge, this is the ﬁrst mechanistic study to investi-
gate a causal link between maternal paracetamol intake and
asthma in early life. We have provided direct in vivo evidence
that maternal paracetamol exposure either during pregnancy,
lactation, or during both, does not affect AHR in offspring
exposed to inhaled HDM. There was also no enhanced inﬂam-
mation, Th2 cytokines or increased levels of serum total or
HDM-speciﬁc IgE. Although expression of early remodelling
genes FIZZ1 and ﬁbronectin were increased at weaning
(3 weeks) following in utero paracetamol exposure, there was
no associated change in protein (total lung collagen) or lung
function, and the differences were not maintained into later life
(6 weeks).
An epidemiological association between paracetamol exposure
during pregnancy and wheezing in early childhood was ﬁrst
demonstrated over a decade ago in the Avon Longitudinal Study
of Parents and Children (ALSPAC) birth cohort.1 Frequent para-
cetamol use, particularly in the latter half of pregnancy, was
associated with persistent wheeze in children at age 3.5 years
and asthma at age 7 years;1 2 the relation with asthma was inde-
pendent of the association between infant paracetamol exposure
and asthma.3 Many other birth cohort studies have since shown
a link between maternal paracetamol use during pregnancy and
the development of wheezing or asthma in children.6
We ﬁrst tried to mimic the effects of in utero exposure alone
by administering paracetamol to female mice only during preg-
nancy, but in contrast to the epidemiological data showing a
Figure 5 Total and house dust mite (HDM)-speciﬁc IgE levels. Serum from HDM-treated or phosphate-buffered saline (PBS)-treated neonatal mice
from either non-paracetamol or paracetamol treated mothers was assessed by ELISA for total IgE (A) or HDM-speciﬁc IgE (B) following 3 weeks or
6 weeks of HDM or PBS exposure. Combined data from two experiments (○ naïve females and ▪ PBS-treated females) or paracetamol-treated
mothers (◊ and ▾) (n=10–12 for control mice and n=11–15 for HDM-exposed mice). Signiﬁcant differences between HDM-exposed and
PBS-exposed neonates from non-paracetamol-treated or paracetamol-treated mothers are shown as **p<0.01 and ***p<0.001. ns, not signiﬁcant.
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positive association between in utero paracetamol exposure and
elevated serum IgE at 7 years,2 we saw no difference in either
total or allergen-speciﬁc IgE levels. In addition, we found no
effect of prenatal paracetamol exposure on any other features of
AAD in our animal model. One explanation may be that the epi-
demiological association with maternal use in pregnancy is
explained by residual or unmeasured confounding factors. For
example, few cohorts had information on indication for use.
A recent, large prospective study designed to look at the effects
of maternal and infant paracetamol ingestion and subsequent
asthma has only shown an association between prenatal para-
cetamol and asthma in early childhood, the effect was not sus-
tained until mid-childhood.26 In order to see whether even a
short-term increase in susceptibility to AAD was present follow-
ing maternal paracetamol exposure, we assessed pups at 3 weeks
and 6 weeks of age. In keeping with the ﬁndings from Sordillo
et al, we saw a transient increase in expression of remodelling
genes only at 3 weeks. However, there was no enhanced effect
on lung function, inﬂammation or sensitisation apparent from
maternal paracetamol at either 3 weeks or 6 weeks.
Another issue is whether infant ingestion may impact subse-
quent asthma development. One epidemiological study demon-
strated that paracetamol ingestion by infants in the 1st year of
life was associated with troublesome lower lung symptoms inde-
pendently of lower respiratory tract infections in the ﬁrst
3 years. There was no association between paracetamol ingestion
during the 1st year and asthma at 7 years of age, or between
maternal paracetamol ingestion during pregnancy and asthma or
troublesome lower lung symptoms.27 Similarly, a much larger
prospective study has shown adjustment for respiratory infec-
tions in early life substantially reduces the association between
infant paracetamol intake and subsequent asthma.26 However,
Figure 6 Increased levels of airway remodelling gene expression in house dust mite (HDM) neonatal mice from paracetamol-treated mothers. RNA
was extracted from lungs from 3-week-old and 6-week-old neonatal mice exposed to HDM or phosphate-buffered saline (PBS), from mothers treated
with paracetamol or PBS during pregnancy alone or lactation alone. mRNA levels for Found In Inﬂammatory Zone (FIZZ)1 (A), vimentin (B),
ﬁbronectin (C), amphiregulin (D), matrix metallopeptidase 2 (MMP)-2 (E) and collagen-1α1 (F) are shown as fold induction normalised to the control
group, PBS-exposed neonates from PBS-treated mothers. Data represents three individual experiments (3 week data) or one representative
experiment (6 week data). Signiﬁcant differences between HDM exposed neonates from control or paracetamol-treated mothers and between PBS
control mice are shown as *p<0.05 and **p<0.01.
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evidence from other epidemiological studies on whether the
link between infant use and asthma is confounded by respiratory
infection is conﬂicting.6 12 Paracetamol can be rapidly secreted
into breast milk and is detectable at higher concentrations in the
milk compared with maternal plasma.17 Furthermore, paraceta-
mol metabolites detected in the urine from babies from breast-
feeding mothers, differ signiﬁcantly from those detected in the
urine of healthy adults who have ingested paracetamol.
Neonates have signiﬁcantly higher levels of paracetamol in their
urine compared with adults, and adults have greater levels of
urinary paracetamol sulfate,17 conﬁrming that the pharmacokin-
etics and pharmacodynamics of paracetamol differ substantially
in murine28 and human neonates and infants compared with
children and adults.29 As it is technically very difﬁcult to
perform oral gavage in newborn mice, the importance of oral
paracetamol ingestion in early life on subsequent AAD was
indirectly determined in our study by administering paracetamol
to mothers only during lactation and assessing AAD just prior to
weaning at 3 weeks. However, we did not see any effect of oral
ingestion via breast milk on the development of AAD in 3 week-
old mice. There was also no long-term effect after weaning in
mice exposed to HDM for 6 weeks. Paracetamol exposure did
not alter inﬂammation or Th2 cytokines and levels of IgE were
also unaffected.
Various genes have now been identiﬁed as important regula-
tors of bronchial subepithelial basement membrane thickening
and as such we analysed the mRNA expression levels of several
ﬁbrotic and early remodelling genes. Interestingly, we found
there was a very small (less than twofold), but statistically signiﬁ-
cant increase in the mRNA levels of ﬁbronectin and vimentin in
allergen-exposed mice from mothers treated with paracetamol
during pregnancy, but not during lactation; whereas FIZZ1 was
upregulated after paracetamol exposure during lactation or preg-
nancy. FIZZ1 is induced in the lung following ovalbumin or
Alternaria challenge,20 30 while ﬁbronectin has been shown to
be essential for the development of ovalbumin-induced airway
ﬁbrosis and AHR.20 Vimentin and ﬁbronectin are also associated
with airway collagen deposition and airway remodelling.21 22
Despite the transient increase in the expression of these genes
we found no change in protein levels of lung collagen in
HDM-treated neonatal mice exposed to maternal paracetamol.
We acknowledge that the ﬁndings from a murine model may
not be directly applicable to the human situation. However,
murine models have been used extensively to study paracetamol
toxicity.31 Furthermore, the transient changes with paracetamol in
FIZZ1, ﬁbronectin and vimentin suggest that paracetamol crosses
the placenta. There is no literature on whether paracetamol
crosses into breast milk of lactating mice, but conversely, there is
no evidence to suggest that breast milk metabolism in mice is sig-
niﬁcantly different from humans. To our knowledge, this is the
ﬁrst mechanistic investigation of a direct effect of paracetamol
exposure either in utero, or orally via breast milk, or at both times,
on neonatal HDM-induced AAD. The strengths include; (1) use of
an age-appropriate model with inhaled allergen challenge, (2)
administration of maternal paracetamol with a similar frequency
and dosage, equivalent to those in epidemiological studies shown
to have effects and (3) absence of any confounding from respira-
tory infections. With these best possible conditions, there was no
effect of maternal paracetamol on the development of any para-
meters of AAD in offspring either in early life (3 weeks of age) or
later at 6 weeks. These data may help to demonstrate why a recent
systematic review of studies looking at the effect of paracetamol in
pregnancy and early life and subsequent asthma has concluded (A)
the association between exposure during pregnancy and asthma in
childhood is highly variable between studies and is not robust, and
(B) the association between paracetamol ingestion in infancy and
subsequent asthma is confounded by respiratory infections.32
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